Spectral AI Secures FDA De Novo Clearance for Burn Wound Diagnostic System

Event summary

  • Spectral AI received FDA De Novo Classification for its DeepView® System on May 26, 2026.
  • The DeepView System is a non-invasive, AI-driven device for assessing burn wound healing potential.
  • The system combines multispectral imaging with a proprietary AI algorithm trained on 340 billion pixels of burn wound data.
  • Spectral AI is now authorized to commence commercial distribution in the U.S.
  • The project is supported by BARDA under contract number 75A50123C00049.

The big picture

Spectral AI's FDA De Novo clearance marks a significant milestone in the integration of AI into medical diagnostics, particularly in wound care. The approval positions the company to capitalize on the growing demand for predictive medical technologies that enhance patient outcomes and reduce healthcare costs. The strategic support from BARDA underscores the potential impact of the DeepView System on public health preparedness and burn care management.

What we're watching

Commercialization Pace
How quickly Spectral AI can scale the commercial distribution of the DeepView System across burn centers, trauma centers, and emergency departments.
Market Adoption
Whether healthcare providers will widely adopt the DeepView System, given its potential to redefine the standard of care in burn wound assessment.
Regulatory Expansion
The pace at which Spectral AI can secure additional regulatory approvals for the DeepView System in other markets.